Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

NEXT STORY
Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors
PREV STORY
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference

SAN DIEGO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics ...

author_avatar
NASDAQ Market News

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations

author_avatar
NASDAQ Market News

Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

- Data from Ongoing Phase 2 Study to be Presented at 1:15 PM CT ...

author_avatar
NASDAQ Market News